Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta‐analysis

Blom, 2005, Malignancies, prothrombotic mutations, and the risk of venous thrombosis, JAMA, 293, 715, 10.1001/jama.293.6.715 Sørensen, 2000, Prognosis of cancers associated with venous thromboembolism, N Engl J Med, 343, 1846, 10.1056/NEJM200012213432504 Agnelli, 2012, Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer, N Engl J Med, 366, 601, 10.1056/NEJMoa1108898 Agnelli, 2009, Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo‐controlled, double‐blind study, Lancet Oncol, 10, 943, 10.1016/S1470-2045(09)70232-3 Akl, 2017, Parenteral anticoagulation in ambulatory patients with cancer, Cochrane Database Syst Rev, 9, CD006652 Kahale, 2017, Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation, Cochrane Database Syst Rev, 12, CD006466 Di Nisio, 2016, Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy, Cochrane Database Syst Rev, 12, CD008500 Lyman, 2015, Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014, J Clin Oncol, 33, 654, 10.1200/JCO.2014.59.7351 Khorana, 2017, Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial, Thromb Res, 151, 89, 10.1016/j.thromres.2017.01.009 Kimpton, 2018, Apixaban for the prevention of venous thromboembolism in high‐risk ambulatory cancer patients receiving chemotherapy: rational and design of the AVERT trial, Thromb Res, 164, S124, 10.1016/j.thromres.2018.01.018 Khorana, 2017, Rivaroxaban for preventing venous thromboembolism in high‐risk ambulatory patients with cancer: rationale and design of the CASSINI trial. rationale and design of the CASSINI trial, Thromb Haemost, 117, 2135, 10.1160/TH17-03-0171 Khorana, 2008, Development and validation of a predictive model for chemotherapy‐associated thrombosis, Blood, 111, 4902, 10.1182/blood-2007-10-116327 Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 DerSimonian, 1986, Meta‐analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Higgins, 2003, Measuring inconsistency in meta‐analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Djulbegovic, 2019, The threshold model revisited, J Eval Clin Pract, 25, 186, 10.1111/jep.13091 Locadia, 2004, Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences, Thromb Haemost, 92, 1336, 10.1160/TH04-02-0075 Levine, 2012, A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer, J Thromb Haemost, 10, 807, 10.1111/j.1538-7836.2012.04693.x Carrier, 2019, Apixaban to prevent venous thromboembolism in patients with cancer, N Engl J Med, 380, 711, 10.1056/NEJMoa1814468 Khorana, 2019, Rivaroxaban for thromboprophylaxis in high‐risk ambulatory patients with cancer, N Engl J Med, 380, 720, 10.1056/NEJMoa1814630 Maraveyas, 2012, Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer, Eur J Cancer, 48, 1283, 10.1016/j.ejca.2011.10.017 Pelzer, 2015, Efficacy of prophylactic low‐molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO‐004 trial, J Clin Oncol, 33, 2028, 10.1200/JCO.2014.55.1481 Kraaijpoel, 2018, Clinical impact of bleeding in cancer‐associated venous thromboembolism: results from the Hokusai VTE Cancer Study, Thromb Haemost, 118, 1439, 10.1055/s-0038-1667001 Verso, 2012, A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score, Intern Emerg Med, 7, 291, 10.1007/s11739-012-0784-y George, 2011, Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit‐risk assessment by VTE risk in SAVE‐ONCO, Blood, 118, 206, 10.1182/blood.V118.21.206.206 Lyman, 2013, Comparative effectiveness research in oncology, Oncologist, 18, 752, 10.1634/theoncologist.2012-0445 Unger, 20191326, Association of patient comorbid conditions with cancer clinical trial participation, JAMA Oncol Lyman, 2013, Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real‐world analysis, Oncologist, 18, 1321, 10.1634/theoncologist.2013-0226 Mahé, 2017, The clinical course of venous thromboembolism may differ according to cancer site, Am J Med, 130, 337, 10.1016/j.amjmed.2016.10.017 Lyman, 2013, Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 31, 2189, 10.1200/JCO.2013.49.1118 Kraaijpoel, 2019, Treatment and long‐term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study, J Clin Oncol, 37, 1713, 10.1200/JCO.18.01977 Decousus, 2018, Cancer‐associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP), Blood, 132, 707, 10.1182/blood-2018-03-837153 Hogg, 2013, Estimating quality of life in acute venous thrombosis, JAMA Intern Med, 173, 1067, 10.1001/jamainternmed.2013.563 Lyman, 2005, The strengths and limitations of meta‐analyses based on aggregate data, BMC Med Res Methodol, 5, 14, 10.1186/1471-2288-5-14 Angelillo, 2003, Meta‐analysis of published studies or meta‐analysis of individual data? Caesarean section in HIV‐positive women as a study case, Public Health, 117, 323, 10.1016/S0033-3506(03)00105-7 Mathew, 1999, On the equivalence of meta‐analysis using literature and using individual patient data, Biometrics, 55, 1221, 10.1111/j.0006-341X.1999.01221.x Sung, 2014, An empirical comparison of meta‐analysis and mega‐analysis of individual participant data for identifying gene‐environment interactions, Genet Epidemiol, 38, 369, 10.1002/gepi.21800